Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04668001 · ClinicalTrials.gov registry record · NA

Transcranial Photobiomodulation With Near-Infrared Light for Language in Individuals With Down Syndrome

A NA study of Down Syndrome, sponsored by Massachusetts General Hospital.

Active
Registry status
NA
Development phase
19
Enrollment target
1
Study location

NCT04668001 is a NA study of Down Syndrome that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 19 participants, below the 2,471-participant average among 54 other Down Syndrome trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04668001, a NA study of Down Syndrome, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
19 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to better understand the effects of transcranial photobiomodulation (tPBM) on neural oscillations of individuals diagnosed with Down syndrome.

Conditions Studied

Interventions

  • DEVICE Near-Infrared Transcranial Photobiomodulation
  • DEVICE Sham Transcranial Photobiomodulation

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital at the Charlestown Navy Yard - Charlestown

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2021-10-19
Est. Completion 2024-09-01
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT04668001

The ClinicalTrials.gov registry entry for NCT04668001 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,471-participant average among 54 other Down Syndrome trials with a reported enrollment target (99% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Down Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Near-Infrared Transcranial Photobiomodulation is the first listed.

NCT04668001 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04668001 about?

NCT04668001 is a clinical study titled "Transcranial Photobiomodulation With Near-Infrared Light for Language in Individuals With Down Syndrome". The aim of this study is to better understand the effects of transcranial photobiomodulation (tPBM) on neural oscillations of individuals diagnosed with Down syndrome.

What is the current status of trial NCT04668001?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 19 participants. The study started on 2021-10-19. Estimated completion is 2024-09-01.

What conditions does trial NCT04668001 study?

This clinical trial studies the following conditions: Down Syndrome.

What interventions are being tested in trial NCT04668001?

The interventions under investigation include: Near-Infrared Transcranial Photobiomodulation (DEVICE), Sham Transcranial Photobiomodulation (DEVICE).

Who is sponsoring clinical trial NCT04668001?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04668001 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Down Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.